SEC Info - Core Laboratories NV - ‘8-K’ for 1/14/20

SEC Info℠

Home

Help

Please Sign In

Core Laboratories NV – ‘8-K’ for 1/14/20

On: Tuesday, 1/14/20, at 4:15pm ET · For: 1/14/20 · Accession #: 1564590-20-1092 · File #: 1-14273

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/14/20  Core Laboratories NV              8-K:7,9     1/14/20   11:186K                                   ActiveDisclosure/FA

Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     36K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     13K 
 9: R1          Document And Entity Information                     HTML     48K 
10: XML         IDEA XML File -- Filing Summary                      XML     11K 
 7: XML         XBRL Instance -- clb-8k_20200114_htm                 XML     15K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- clb-20200114_lab                      XML     58K 
 5: EX-101.PRE  XBRL Presentations -- clb-20200114_pre               XML     35K 
 3: EX-101.SCH  XBRL Schema -- clb-20200114                          XSD     19K 
 6: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
 8: ZIP         XBRL Zipped Folder -- 0001564590-20-001092-xbrl      Zip     12K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i CORE LABORATORIES N V i 00-0000000 i 0001000229 0001000229 2020-01-14 2020-01-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i January 14, 2020

CORE LABORATORIES N.V.

(Exact name of registrant as specified in its charter)

The i Netherlands	i 001-14273	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

i Strawinskylaan 913 Tower A, Level 9 i i 1077 XX / i Amsterdam The i Netherlands		Not Applicable
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: ( i 31-20) i 420-3191

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

i Common Stock (Par Value EUR 0.02)

i CLB

i New York Stock Exchange

Common Stock (Par Value EUR 0.02)

CLB

Euronext Amsterdam Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 14, 2020, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.25 per share of common stock for shareholders of record on January 24, 2020 and payable February 14, 2020.

The full text of the press release is set forth in Exhibit 99.1 attached hereto.

The information in this Report and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits


	(d)		Exhibits

99.1Press release issued on January 14, 2020 *

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.

CORE LABORATORIES N.V.

EXHIBIT INDEX TO FORM 8-K



EXHIBIT NO.		ITEM

99.1		Press release issued on January 14, 2020 *
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	Core Laboratories N.V.

Dated: January 14, 2020	By	/s/ *Christopher S. Hill*
		Christopher S. Hill
		Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

	2/14/20	SC 13G/A
	1/24/20
Filed on / For Period end:	1/14/20
		List all Filings

↑Top

Filing Submission 0001564590-20-001092 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)